Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nurix Therapeutics

11.49
-0.1300-1.12%
Post-market: 11.490.00000.00%17:10 EDT
Volume:1.48M
Turnover:17.04M
Market Cap:875.95M
PE:-4.10
High:11.88
Open:11.73
Low:11.22
Close:11.62
Loading ...

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

GlobeNewswire
·
02 Apr

BRIEF-Nurix Therapeutics Announces Multiple Presentations At The American Association For Cancer Research (AACR) 2025 Annual Meeting

Reuters
·
26 Mar

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely

Simply Wall St.
·
22 Mar

Nurix Therapeutics Initiated at Market Perform by Leerink Partners

Dow Jones
·
17 Mar

Nurix Gets FDA Orphan Designation for Bexobrutideg in Waldenstrom Macroglobulinemia

Dow Jones
·
17 Mar

Nurix Therapeutics' Blood Cancer Drug Candidate Gets FDA Orphan Drug Designation

MT Newswires Live
·
17 Mar

Nurix Therapeutics Inc : Leerink Partners Initiates Coverage With Market Perform Rating; Price Target $16

THOMSON REUTERS
·
17 Mar

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (Nx-5948) for the Treatment of WaldenstrÖM Macroglobulinemia

THOMSON REUTERS
·
17 Mar

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

GlobeNewswire
·
17 Mar

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
15 Mar

Nurix Therapeutics treatment of Waldenstrom macroglobulinemia gets orphan status

TIPRANKS
·
14 Mar

Press Release: Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

Dow Jones
·
14 Mar

Nurix Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
04 Mar

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
15 Feb

Truist Financial Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)

TIPRANKS
·
03 Feb

Nurix Therapeutics Inc. : Morgan Stanley Raises Target Price to $17.00 From $16.00

THOMSON REUTERS
·
03 Feb

Nurix Therapeutics Faces Financial Risks Amid Supreme Court Regulatory Shift

TIPRANKS
·
30 Jan

Nurix Therapeutics Reports Solid Progress and Strong Pipeline

TIPRANKS
·
30 Jan

Nurix Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
30 Jan

Nurix Therapeutics’ Strategic Advancements and Promising Clinical Developments Justify Buy Rating

TIPRANKS
·
29 Jan